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Copyright © 2008 JCBN Summary Intestinal ischemia/reperfusion (I/R) injury occurs frequently in a variety of
clinical settings, including mesenteric artery occlusion, abdominal aneurism surgery, trauma,
shock, and small intestinal transplantation, and is associated with substantial morbidity and
mortality. Although the exact mechanisms involved in the pathogenesis of intestinal I/R injury
have not been fully elucidated, it is generally believed that polymorphonuclear neutrophils,
pro-inflammatory cytokines, and mediators generated in the setting of oxidative stress, such
as reactive oxygen species (ROS), play important roles. Heme oxygenase (HO) is the rate-
limiting enzyme that catalyzes the degradation of heme into equimolar quantities of biliverdin
and carbon monoxide (CO), while the central iron is released. An inducible form of HO
(HO-1), biliverdin, and CO, have been shown to possess generalized endogenous anti-
inflammatory activities and provide protection against intestinal I/R injury. Further, recent
observations have demonstrated that exogenous HO-1 expression, as well as exogenously
administered CO and biliverdin, have potent cytoprotective effects on intestinal I/R injury as
well. Here, we summarize the currently available data regarding the role of the HO system in
the prevention intestinal I/R injury.
Key Words:intestinal ischemia reperfusion injury, heme oxygenase, carbon monoxide, 
biliverdin, reactive oxygen species
Introduction
Despite improvements in surgical technique and pharmaco-
logical strategies over the past several decades, intestinal
ischemia/reperfusion (I/R) injury remains a clinically
significant problem [1–3]. A delay in either the diagnosis of
intestinal ischemia or in the implementation of effective
treatment may cause gangrenous necrosis of the gut. Even
after successful reintroduction of blood flow is obtained
following bowel ischemia, reperfusion of ischemic gut can
potentially worsen acute intestinal injury due to generationIntestinal I/R Injury and HO-1, CO and Biliverdin
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of reactive oxygen species (ROS), which are known to play
a critical role in gut epithelial cell damage. Although the
exact mechanisms involved in the pathogenesis of intestinal
I/R injury have not been fully elucidated, intestinal I/R
injury is a major cause of morbidity and mortality, as the
intestine is very susceptible to I/R injury and I/R injury
results in systemic complications, including bacterial trans-
location and multiple organ failure [4].
A number of therapeutic modalities have been used to
attenuate intestinal I/R injury in both experimental and
clinical studies. The heme oxygenase (HO) enzymes are
catalysts for the rate-limiting step in the conversion of heme
into biliverdin, carbon monoxide (CO) and free iron [5].
Recently, activity of the inducible form of HO, HO-1, as
well as the byproducts of the HO system, including both CO
and biliverdin, have been shown to exert potent cellular
protective effects by virtue of their anti-inflammatory, anti-
apoptotic and anti-oxidant actions against oxidative stress in
various settings [6, 7]. The optimal therapeutic approach is
dependent upon an understanding of pathophysiology of
intestinal I/R injury and mechanism of the potential strategies
aimed at ameliorating I/R injury. Among these potential
therapeutic options, application of the HO system might be
one of the most promising approaches. The aim of this
review is to provide an outline of current knowledge of the
HO system and the feasibility of this approach for
preventing intestinal I/R injury.
The Heme Oxygenase System
Initially, HO was recognized as the enzyme responsible
for heme catabolism by opening its tetrapyrrole ring struc-
ture to yield CO, biliverdin, and free iron [5]. Biliverdin is
rapidly reduced to bilirubin by biliverdin reductase (Fig. 1).
Since inducible HO-1 was discovered and found to be a
stress-responsive protein with broad cytoprotective proper-
ties, interest in the HO system has been renewed and it has
attracted the attention of the scientific community world-
wide [8, 9].
To date, three isoforms (HO-1, HO-2 and HO-3) have
been identified. HO-2 is for the most part a constitutively
synthesized protein existing in the brain and testis [8, 10].
HO-3, a recently cloned gene, is also involved in heme
degradation, but is a less efficient heme catalyst than HO-2
[11]. In contrast, the “inducible” isoform, HO-1, is a ubiq-
uitous heat shock protein (HSP32) that is highly induced
by diverse stress-related conditions [12]. It is upregulated in
response to oxidative stress, hyperthermia, and proinflam-
matory stimuli in a variety of tissues, and has been shown to
exert potent cytoprotective and anti-apoptotic properties,
providing generalized endogenous anti-inflammatory
protection against oxidative stress [13]. Although the
beneficial roles of HO-1 are not completely understood,
there is accumulating evidence that endogenous induction of
HO-1 in the setting of various stressors is indispensable for
the survival of organisms. Poss and Tonegawa generated
HO-1 deficient mice by targeted deletion of the mouse HO-
1 gene. Mice lacking the HO-1 gene frequently die in utero,
and the mice that survive to adulthood exhibit growth
failure, anemia, chronic inflammation characterized by
hepatosplenomegaly, leukocytosis, glomerulonephritis, and
histological hepatoportal cellular infiltration [14,  15]. A
human patient that was HO-1-deficient, who unfortunately
died in his childhood, demonstrated clinical manifestations
similar to those observed in HO-1 deficient mice, including
growth failure, anemia, tissue iron deposition, lymphoadeno-
pathy, leukocytosis and increased sensitivity to oxidative
injury [16]. These observations strongly support the
evolving paradigm that HO-1 serves to provide cytoprotec-
tion against oxidative stress and is necessary in mammals.
One possible explanation for the protective role of HO-1
may be the removal of free heme. Free heme is highly
lipophilic and will rapidly intercalate into the lipid
membranes of adjacent cells, and activate vascular endo-
thelial cells resulting in an upregulation of adhesion
molecules or E-selectin [17]. More importantly, free heme
derived from degraded hemoglobin protein during I/R injury
has been implicated as the source of catalytic iron that would
participate in the Fenton reaction, converting H2O2 to more
reactive hydroxyl radicals and promoting more severe tissue
damage by propagating lipid peroxidation. Thus, the HO
system is equipped to cope with the problems caused by
intracellular high protein-unbound, free heme concentra-
tions. Furthermore, because HO-1 functions by catabolizing
heme to biliverdin, iron, and CO, these byproducts of heme
degradation are believed to be effector molecules underlying
the potent cytoprotection observed with the HO system [10,
18,  19]. Thus, in addition to removal of the pro-oxidant
heme, in turn, the breakdown of heme to three byproducts
has its own significance in essential cellular metabolism and
contributes to the suppression of oxidative stress [20–22].
Also, the beneficial role of the HO-1 system was substanti-
ated when exogenous HO-1 was demonstrated to ameliorate
tissue injury and induce cytoprotection [23–26].
Fig. 1. Heme Oxygenase SystemA. Nakao et al.
J. Clin. Biochem. Nutr.
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Intestinal Ischemia/Reperfusion (I/R) Injury
Clinical significance of intestinal I/R injury
Intestinal I/R injury occurs frequently in a variety of
clinical settings, including surgical treatment for abdominal
aortic aneurysm, mesenteric artery occlusion, cardio-
pulmonary bypass, bowel strangulation, neonatal necro-
tizing enterocolitis and small intestinal transplantation
[27–31]. Of note, severe hemorrhagic shock also causes
intestinal I/R injury. The systemic response against a
decrease in blood pressure or blood volume is characterized
by the preferred maintenance of the centralized blood flow,
leading to disproportionate splanchnic vasoconstriction, and
with resuscitation, the reperfused gut initiates a proinflam-
matory response that contributes to both local gut and
remote organ injury [32, 33]. This vascular phenomenon may
partially explain the susceptibility of intestine to I/R injury.
It is generally accepted to conceptually divide I/R injury
into two categories of those following warm ischemia and
cold ischemia [34]. Warm I/R injury usually occurs after
temporal reduction or cessation of blood flow to the intestine
in warm condition (usually body temperature). On the other
hand, cold ischemia is only experienced by some hibernators
or by cadaveric donor organs being preserved at low
temperature, which is widely-used technique to preserve
organs prior to transplantion during the time required to
transfer the graft from the donor to the recipient. Hypo-
thermia (cold temperature; usually <4°C) is employed to
slow the rate of cellular metabolism and delay the onset of
cell death; however hypothermia introduces unique and
new forms of cellular damage. Hypothermia suppresses the
Na+/K+ pump, leading to cellular swelling. Also, cellular
damage is accelerated by an increase in chelatable iron and
mediated by mitochondrial permeability transition, so-called
“chilly injury” [35].
Warm and cold I/R injury cause similar injury after
reperfusion [36]. In both types of I/R injury, the intestine
with I/R injury can be a source of pro-inflammatory
mediators that enhances local intestinal injury and dysfunc-
tion, and activates circulating neutrophils that cause remote
organ injury. If severe enough, the inflammatory response
after I/R may result in the systemic inflammatory response
syndrome and multiple organ failure (MOF), which account
for 30–40% of the mortality in tertiary referral intensive care
units [37]. Thus, I/R injury may extend beyond the ischemic
area at risk to include injury of remote, nonischemic organs.
Interestingly, the colon is more resistant to ischemia than
small intestine in both warm and cold I/R canine models,
although the reasons for the difference between the suscepti-
bility of the colon and the small intestine to I/R injury have
not been elucidated [38].
Experimental models of bowel I/R injury
A simple and reliable animal model can be used to study
the pathophysiology of intestinal I/R injury, as well as
evaluate potential treatments for this problem. Superior
mesenteric artery occlusion (SMAO) and revascularization
have been used as reproducible models of warm I/R injury
in small or large animals. In this model, the magnitude of
I/R injury is time-dependent. The intestinal function of
absorption-secretion, the blood flow, the cellular integrity,
the mucosa wall, its motility and the hormonal function of
the intestinal tract are impaired. Hemorrhagic shock and
resuscitation is another well-defined model where intestinal
I/R injury is observed. Typically, anesthetized animals are
subjected to hemorrhagic shock by shedding blood with a
mean arterial pressure (MAP) of ~40 mmHg or less, and
then the animals are resuscitated with the fluid or blood.
A clinically relevant model of cold I/R injury is intestinal
transplantation. Intestinal transplantation procedures neces-
sitate cold preservation and are followed by warm reperfu-
sion of the grafts, resulting in some degree of cold I/R injury
in the intestinal grafts. Harvested organs are subjected to
further damage at the time of reperfusion when warm
oxygenated blood is reintroduced into the graft (warm
reperfusion).
Mechanisms of intestinal ischemia/reperfusion injury
Multiple factors have been shown to be involved in the
process of intestinal I/R injury. However, intestinal I/R
injury basically consists of two specific stages; the
ischemic stage, or hypoxemia, and the revascularization
stage, or the reintroduction of oxygen into the ischemic
intestine. During ischemic stage, the lack of oxygen results
in decreased production of adenosine triphosphate (ATP).
As the consumption of ATP continues, ATP is degraded into
adenosine diphosphate (ADP), adenosine monophosphate
(AMP) and further to adenosine, which is then degraded to
inosine and hypoxanthine. While hypoxanthine is metabo-
lized to uric acid in the normoxic condition, hypoxanthine is
not converted to uric acid and accumulates in the ischemic
tissues during hypoxia [39]. ATP depletion leads to
alterations in intracellular calcium and sodium concentra-
tions and activation of cytotoxic enzymes, such as proteases
or phospholipases, ultimately resulting in cell damage.
On reperfusion, as molecular oxygen is reintroduced in
the hypoxic intestine, oxygen reacts with hypoxanthine and
xanthine oxidase to generate superoxide anion (·O2−) and
hydrogen peroxide (H2O2). The superoxide anion requires an
additional electron to make it more stable, so it steals an
electron from the nearest source, such as mitochondrial
DNA or the mitochondrial membrane, causing mitochon-
drial damage via lipid peroxidation. These initial ROS
(·O2− and H2O2) are not only detrimental, but also signal
transduction molecules involved in several signaling cascadesIntestinal I/R Injury and HO-1, CO and Biliverdin
Vol. 42, No. 2, 2008
81
affecting numerous cellular processes including inflamma-
tion and apoptosis [40]. The hydroxyl radical, the most
detrimental ROS in I/R injury process, is generated in
biological systems from superoxide anion and hydrogen
peroxide by the Haber-Weiss reaction or from hydrogen
peroxide by the Fenton reaction in the presence of iron
[41, 42]. Hydroxyl radicals easily react with cellular macro-
molecules, including DNA, proteins and lipids, and give rise
to I/R injury-originated intestinal damage (Fig. 2). In addi-
tion, both ·O2− and H2O2 can interact with nitric oxide (NO)
and form highly reactive peroxynitrite (ONOO-) [43].
Pathophysiology of intestinal I/R
Typically, the intestinal damage by I/R injury starts at the
villus layer of the mucosa. There are several explanations for
the exquisite susceptibility of intestinal mucosa to I/R injury.
Physiologically, the high baseline rate of oxygen use by
intestinal mucosa renders the intestine relatively incapable
of increasing oxygen transport in the face of hypoxic stress
and thus more susceptible to ischemic injury [44]. Anatomi-
cally, the villous microcirculation is characterized by a
peculiar vascular network consisting of centrally located
arterial vessels and a subepithelial network of small veins
and capillaries. This unique communication of vessels may
result in regional hypoxia at the villous tip, even though the
overall oxygen extraction efficiency of the gut may be high
[45]. Furthermore, leukocyte-endothelial cell interaction and
capillary perfusion failure occur [46]. The malperfusion of
intestine is also associated with a marked alteration in
lymphatic capillary drainage of the villi.
Microscopic criteria for grading of intestinal tissue injury
was reported by Park et al. and has been frequently used for
evaluating the efficacy of various pharmacological manipu-
lations aimed at modulating intestinal ischemia and its
consequences [29, 47]. Grade 0 is defined as normal mucosa
and grades 1 to 5 indicate increasing degrees of villous
damage. The pathological feature in grade 1 is the develop-
ment of a subepithelial space at the tip of the villi
(Gruenhagen’s space). This space is more pronounced in
grade 2, and turns to massive epithelial lifting down the side
of the villi in grade 3. The villi are denuded of epithelium in
grade 4, and lost in grade 5. In grade 6, the crypt layer
infarction is seen. In grade 7, the entire intestinal mucosa is
necrotic and grade 8 depicts transmural infarction [29].
Apart from necrosis, programmed cell death, or apoptosis,
is a common cellular response to oxidative injury. Although
resultant epithelial cell death has been attributed to necrosis,
it is obvious that apoptosis occurs after I/R injury [48].
We have previously demonstrated that I/R injury induces
apoptosis in the intestinal mucosa [49]. Only the procedure
of cold storage results in villous and crypt apoptosis [50].
Inflammation
Various inflammatory mediators have been implicated in
intestinal I/R injury. Of these mediators, the inflammatory
cytokines including tumor necrosis factor (TNF)-α and
interleukin (IL)-1β are known to play an important role in
the early period of inflammatory response of warm I/R
injury. Yamamoto et al. demonstrated that plasma TNFα and
IL-1β levels were significantly elevated and this occurred in
association with increased blood endotoxin levels and
mucosal injury. These changes were inhibited by FR167653,
a specific IL-1β and TNF inhibitor, suggesting a critical
role of TNFα and IL-1β in the pathophysiology of intestinal
I/R injury [51]. Interestingly, the elevation of TNFα is not
dramatic in a cold I/R model [52]. These inflammatory
reactions are related to the expression of adhesion molecules
such as P- and E-selectins [53].
Ileus (intestinal dysmotility)
Ileus, defined as impaired propulsive bowel motility,
frequently occurs in association with intestinal I/R injury
[54–56]. An inverse correlation between post-ischemic
gastrointestinal motility and the duration of intestinal warm
ischemia was reported by Udassin et al. [57]. The develop-
ment of ileus results in abdominal distention, nausea, and
emesis. In some instances, ileus can contribute to the
development of more serious complications, including
acute gastric dilatation, pulmonary aspiration, respiratory
compromise, cardiac arrhythmias, or intestinal perforation.
Furthermore, because ileus precludes oral intake of food or
fluids, patients recovering from severe disease status are
routinely provided with water, essential electrolytes, glucose
and analgesics via parenteral routes of administration.
However, in the absence of ileus, intravenous fluids and/or
parenteral analgesics would be unnecessary in many cases,
and, thus, the typical period of hospitalization after abdominal
surgery could be greatly shortened.
The pathogenesis of ileus is multifactorial, but inflam-
mation of the gut wall plays a major role. A rat model of
intestinal I/R injury after hemorrhagic shock demonstrated
Fig. 2. Reactive oxygen species involved in I/R injuryA. Nakao et al.
J. Clin. Biochem. Nutr.
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that the development of ileus is accompanied with inter-
cellular adhesion molecule expression and neutrophil infil-
tration in the intestine [58]. The cellular responses after
warm ischemia were preceded by the molecular activation of
nuclear factor kappa B, upregulation of granulocyte colony-
stimulating factor and IL-6 mRNA and phosphorylation of
the downstream signaling and transcription factor Stat3 [59].
Inducible nitric oxide synthase is upregulated after severe
intestinal I/R injury insult and mediates ileus development
[60].
Bacterial translocation
An important function of the intestinal mucosa is to
provide a selective barrier that facilitates the absorption of
nutrients while preventing translocation of bacteria and
absorption of their toxic products. Intestinal I/R injury has
been shown to increase mucosal permeability, which is
associated with the development of MOF in patients [61–
63]. Damage of the mucosal layer by I/R injury allows
enhanced uptake of proteolytic enzymes, bacteria, and
endotoxin from the intestinal lumen into circulation.1 This
damage adversely affect cardiac and respiratory function,
and together with the release of cardiodepressant substances,
may create a vicious circle in which impaired heart function
leads to a progressive deterioration of intestinal perfusion.
This in turn, results in a further reduction of flow to outer
layers of intestine, leading ultimately to total bowel infarc-
tion [64]. The increase in intestinal permeability caused by
I/R injury is one of the important factors leading to bacterial
translocation [65]. Bacterial translocation was seen in 44%
of pediatric patients that underwent small intestinal trans-
plantation [2].
The Efficacy of the HO-1 System for the Prevention
of Intestinal I/R Injury (Table 1)
HO-1 induction protects the intestine from I/R injury
As discussed above, activation of the HO-1 system
confers cytoprotective effects during the cascade of events
caused by I/R injury [66, 67]. In this regard, HO-1 over-
expression can be achieved by either exogenously adminis-
tration of HO-1 or enhancement of endogenous HO-1.
Exogenous administration of HO-1 by gene transfer could
be a specific and attractive approach [23]; however, the use
of viral vectors in clinical practice is currently very limited
and more studies are necessary to show the efficacy and
safety of selectively delivering HO-1 in this manner. As far
as we know, HO-1 gene transfer as a therapeutic strategy for
intestinal I/R injury has not been reported.
On the other hand, there are several pieces of evidence
that suggest that induction of endogenous HO-1 through
various pharmacological approaches can ameliorate intes-
tinal I/R injury. Ferric protoporphyron (Hemin) is a substrate
of HO-1. Attuwaybi et al. showed that treatment with Hemin
Table 1. The Efficacy of the HO-1 System for the Prevention of Intestinal I/R Injury
Author Year Journal treatment Animal I/R model reference
HO-1
Wasserberg 2007 Int J Surg Cobalt protoporphyrin (CoPP) rat warm ischemia (60 min) [70]
Mallick 2005 World J Gastroenterol pyrrolidine dithiocarbamate (PDTC) rat warm ischemia (30 min) [72]
Mallick 2005 Microcirculation Ischemic preconditioning rat warm ischemia (30 min) [79]
Sakamoto 2005 Int J Hyperthermia hyperthermia (42–43°C) rat warm ischemia (30 min) [80]
Attuwaybe 2004 J Trauma Hypertonic saline rat warm ischemia (60 min) [73]
Attuwaybe 2004 J Surg Res hemin rat warm ischemia (60 min) [68]
Nussler 2003 Ann Surg IL-2 rat warm ischemia (60 min) [74]
Attuwaybe 2003 J Surg Res hypothermia (15°C locally) rat warm ischemia (75 min) [81]
Tamion 2002 Am J Physiol Ischemic preconditioning rat hemorrhagic shock followed by resuscitation [78]
Tamion 2001 Am J Respir Crit Care Med hemoglobin rat hemorrhagic shock followed by resuscitation [69]
Tamaki 1999 Transplant Proc glutamine rat warm ischemia (60 min) [73]
Carbon monoxide
Nakao 2006 Am J Transplant ex vivo (5% CO bubbling) rat intestinal transplants (6 hrs cold ischemia) [52]
Nakao 2003 Am J Pathol inhalation (250 ppm) rat intestinal transplants (6 hrs cold ischemia) [87]
Nakao 2003 GUT inhalation (250 ppm) rat intestinal transplants (1 hr cold ischemia) [86]
Nakao 2003 Surgery inhalation (250 ppm) rat intestinal transplants (6 hrs cold ischemia) [85]
Biliverdin/bilirubin
Nakao 2004 Gastroenterology biliverdin (ip) rat intestinal transplants (6 hrs cold ischemia) [62]
Ceran 2001 J Pediatr Surg bilirubin (iv) rat warm ischemia (45 min) [101]
Hammerman 2002 J Pediatr Gastroenterol Nutr bilirubin (iv) rat warm ischemia (45 min) [102]Intestinal I/R Injury and HO-1, CO and Biliverdin
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(50 µmol/kg, subcutaneously) 2 hours prior to warm I/R
injury resulted in increased HO-1 protein expression,
reduced mucosal injury, decreased myeloperoxidase (MPO)
activity, and improved intestinal transit following gut I/R
[68]. Likewise, the pretreatment with hemoglobin induces
HO-1 and significantly reduced systemic inflammations
associated with plasma concentrations of TNFα levels due
to intestinal I/R injury in one study [69].
Administration of a chemical inducer of HO-1, cobalt
protoporphyrin (CoPP), at 24 hours prior to ischemic insult
significantly reduced intestinal tissue injury due to warm I/R
injury [70]. Pyrrolidine dithiocarbamate (PDTC), which is
used as an antioxidant and a metabolic inhibitor of a variety
of biological reactions, including activation of transcription
factor NF-kB, is known to induce HO-1. Mallick et al. have
reported that PDTC treatment improved intestinal micro-
vascular perfusion and attenuated I/R injury [71,  72].
Glutamine and IL-2 have been also reported to induce HO-1
and prevent intestinal I/R injury, respectively [73,  74].
Recently, interest in hypertonic saline (HTS) has resurfaced,
as recent laboratory studies documented that HTS resuscita-
tion profoundly modulates inflammation after hemorrhagic
shock partly due to its ability to induce HO-1 [75,  76].
Although several clinical randomized trials designed to test
the efficacy of HTS in resuscitation have failed to document
a consistent outcome advantage, the use of HTS for
hemorrhagic shock may open new therapeutic windows
because of its unique mechanisms [77].
Non-pharmacological induction of HO-1 is also known to
be protective for intestinal I/R injury. Ischemia precondi-
tioning (IPC) refers to the phenomenon by which exposure
of tissues to brief periods of ischemia protects them from the
harmful effects of prolonged I/R injury. Although the
mechanisms underlying the protective actions of IPC have
not been fully elucidated, recent evidence has suggested
that the protective effects of ischemic preconditioning are
attributable to expression of HO-1 [78, 79]. Tamion et al.
have demonstrated that intestinal IPC with four cycles of
1 min ischemia and 10 min of reperfusion induced intestinal
HO-1 and significantly reduced systemic inflammatory
reactions related to intestinal I/R injury. These effects were
abolished by tin protoporphyrin (SnPP), a HO-1 inhibitor.
Whole body hyperthermia to a core temperature of 42–
43°C for 15 min significantly induced the production of
heat shock protein-70 (HSP70) and HO-1 in intestinal
mucosa and significantly reduced I/R-induced mucosal
injury. The combination of zinc protoporphyrin (ZnPP, an
HO-1 inhibitor) with hyperthermia extinguished the protec-
tive effects of hyperthermia on I/R injury, suggesting that the
protective effects of hyperthermia are mediated by HO-1
expression [80]. Interestingly, Attuwaybi et al. revealed that
regional hypothermia induces HO-1 and protected intestine
from warm I/R injury [81]. Likewise, these protective
effects were abrogated by SnPP.
Carbon monoxide (CO) prevents intestinal I/R injury
In accordance with the increasing number of studies about
HOs, a new paradigm has been emerging that CO, one of
byproducts through heme degradation by HO, functions as a
signaling molecule that exerts significant cytoprotection due
to its anti-inflammatory, vasodilating, and anti-apoptotic
properties [82–84]. Similar to what has been observed with
HO-1, CO has been demonstrated to mediate potent cyto-
protective and anti-inflammatory effects during oxidative
stress, hyperoxic lung injury, endotoxemia, and rejection of
the liver, heart and lung [18, 19].
We have shown the efficacy of CO gas inhalation for the
prevention of cold intestinal I/R injury using a small intes-
tinal transplantation model. Recipient treatment with CO at
250 ppm 1 hour before and 24 hours after reperfu-
sion effectively inhibited an early up-regulation of pro-
inflammatory mediators, yielded less severe histopatholog-
ical changes, and resulted in significantly improved animal
survival compared to air-treated controls [85, 86]. CO also
significantly reduced mRNA for proapoptotic Bax, while it
up-regulated anti-apoptotic Bcl-2. The protective effects of
CO in this study were mediated via soluble guanylyl
cyclase, as 1H-(1,2,4)oxadiazole (4,3-alpha) quinoxaline-1-
one (ODQ; a soluble guanylyl cyclase inhibitor) completely
reversed the beneficial effect conferred by CO, suggesting
that the effects of CO was mediated by activation of soluble
guanylyl cyclase [87].
Since CO is gaseous molecule, inhalation of CO is
straightforward delivery method for utilization of the HO
systems that can be applied in the clinical setting. However,
CO has long been known as a toxic gas due to its ability
to interfere with oxygen delivery. To overcome these
problematic aspects and minimize the concerns associated
with  in vivo CO gas administration to patients, ex vivo
application of CO gas might be another way to deliver CO.
Our group has previously shown that cold storage in a
preservation solution that was bubbled with 5% CO signifi-
cantly reduced I/R injury associated with intestinal trans-
plantation [52].
Biliverdin/bilirubin prevent intestinal I/R injury
Similar to CO, recent evidence has indicated that
biliverdin and bilirubin, synthesized as byproducts of the
enzymatic reaction of catalyzed by HO, serve as a key
mediators that help maintain the integrity of the physio-
logical function of organs [88, 89]. In particular, it is well
known that these bile pigments have antioxidant activities
[90]. Bilirubin is the most abundant endogenous antioxidant
and accounts for the majority of the anitioxidant activity in
human serum [91]. In the general population, high serum
bilirubin levels correlate with a reduced risk of ischemicA. Nakao et al.
J. Clin. Biochem. Nutr.
84
heart disease [92–95] and a lower incidence of retinal
damage in newborns [96–98]. Although both biliverdin and
bilirubin possess anti-oxidant activities, most of the actions
are attributed to bilirubin via H-donation to an incipient
radical, such as a lipid peroxyl radical (LOO·), to form lipid
hydroperoxide (LOOH) and bilirubin radical [99]. Oxidation
of bilirubin by ROS results in the conversion of bilirubin to
biliverdin, which is a precursor of bilirubin in the heme
degradation and is recycled to bilirubin by biliverdin
reductase in mammals. This recycling between bilirubin and
biliverdin is believed to be behind one of the explanations
for bilirubin’s powerful antioxidant effects in the redox
cycle [100].
Ceran et al. demonstrated that bilirubin has potent protec-
tive effects in an experimental of small intestinal warm I/R
injury in rats [101]. The intravenous injection of 20 mg/kg
of bilirubin completely prevented mucosal injury and was
associated with less lipid peroxidation and fewer histo-
logical changes. Similar results were also reported by
Hammerman et al., who also demonstrated that hyperbiliru-
binemia (14.9 ± 5.7 mg/dl) derived from intravenous injec-
tion of bilirubin attenuated intestinal warm I/R injury [102].
Administration of biliverdin to rodents has been shown to
provide anti-oxidant protective effects in a rat intestinal cold
I/R model. Biliverdin administration attenuates transplanta-
tion-induced I/R injuries to the small bowel by its anti-
inflammatory and anti-oxidant actions [62]. The potential
toxic actions of bile pigments range from itching in
jaundiced patients to severe neuronal damage, primarily in
the basal ganglia, as observed in kernicterus. Further
examination will be required to assess the long-term
outcomes after treatment with bile pigment; however, short
term follow has not revealed any adverse effects [103].
Conclusions
As shown here, accumulating experimental evidence has
clearly revealed that HO-1 overexpression and/or its
enzymatic byproducts, including CO or biliverdin, confer
protective effects against intestinal I/R injury. HO-1 related
pharmacological research is a rapidly emerging field, which
is likely to yield a number of therapeutic possibilities for
patients in the clinical setting. Therefore, it will be important
to explore the therapeutic potential of HO-1 inducers and
byproducts of the HO system.
As far as we know, there have been no definitive trials
designed to evaluate the efficacy chemical HO-1 inducers in
the clinical setting. However, there are increasing reports
showing that several drugs that are already in use clinically
can induce HO-1 [104]. IPC with brief periods of inter-
mittent ischemia, a known potent anti-oxidant intervention,
might be used as a tool to prevent the local intestinal I/R
injury and the associated systemic inflammatory response.
Similarly, several clinical trials designed to evaluate the
efficacy and safety of inhaled CO for various disease states
have been initiated [105]. CO inhalation at a low concentra-
tion is applicable for in number clinical settings, and may be
particularly useful in patients that are mechanically
ventilated. An alternative and promising approach for CO
delivery may include the use of CO-releasing molecules,
which have been shown to exert vascular and cytoprotective
activities that are reminiscent of the HO-1/CO pathway
[106]. Intraperitoneal injection of CO-saturated solutions
might be applicable as a simple procedure [107]. Alterna-
tively, biliverdin/bilirubin may be more applicable for
clinical use than a pharmacologic HO-1 inducer or CO.
Indeed, a preliminary clinical report revealed the effective-
ness of Goou and Yutan, traditional Chinese drug containing
biliverdin, for the treatment of chronic liver disease [108].
Furthermore, it has been shown that therapy involving the
combination of CO and biliverdin has additive effects in
preventing I/R injury following heart or renal transplantation
[21]. Considering the sensitivity of the small bowel to I/R
injury, the severity of its consequences, I/R injury in intes-
tinal transplantation may be one of the best candidates for
early clinical application of these therapeutics.
In conclusion, HO-1 system including CO and biliverdin/
bilirubin may serve as promising potential therapeutic
options for intestinal I/R injury, although further toxico-
logical studies will be required before they can be employed
as drugs in the clinical setting. A more comprehensive
understanding of the toxicity, pharmacokinetics, and biology
of HO-1-related molecules will certainly help to allow us to
harness the protective potential the HO-1 system prior to
clinical application of theses therapeutics for the prevention
intestinal I/R injury. The scientists working in HO-related
field should not lose sight of the clinical patients, for whom
the research is being conducted.
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